Cost-Effectiveness of Cerebrolysin^®

Cost-effectiveness analysis plays a crucial role in guiding policy decisions and shaping clinical practice guidelines, as healthcare systems globally endeavor to optimize resource allocation and improve patient outcomes.

The evaluation of emerging therapies, especially for conditions such as stroke, is crucial for delivering optimal care and ensuring financial sustainability. By integrating economic evaluations into decision-making processes, efficient resource utilization and the adoption of valuable therapies, can be identified.

Analysing the cost-effectiveness profile of Cerebrolysin^® provides valuable insights for policymarkers and healthcare providers, considering the specific needs and constraints of the local environment.

The continuative analysis of the CARS study offers a unique opportunity to assess the cost-effectiveness of Cerebrolysin^® for different cost scenarios using real-world data from a well-designed clinical trial.

The findings of this evaluation can help to bridge the gap between clinical efficacy and the economic implications of Cerebrolysin^® as an add-on therapy for moderate to severe acute ischemic stroke.

CONCLUSION:
The results indicate a favorable cost-effectiveness profile for Cerebrolysin^® add-on treatment in moderate–severe acute ischemic stroke.

• A treatment with Cerebrolysin^® is cost-effective in 80% of cases
• Cerebrolysin^® mainly reduces event costs due to early remobilization and in addition, rehabilitation and nursing-home costs
• Cerebrolysin^® add-on scheme has a beneficial impact on the quality of life of ischemic stroke patients
• Findings are in line with the existing literature on this topic